- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04835207
Metabolic Profile as a Predictor of No-reflow in Diabetic Patients
Metabolic Profile as a Predictor of No-reflow in Diabetic Patients Treated With Primary Percutaneous Coronary Intervention ( PCI ) .
Study Overview
Status
Conditions
Detailed Description
Acute myocardial infarction (AMI) with its accompanying adverse sequelae is one of the most common causes of morbidity and mortality in the world .
Although reperfusion techniques for ST- elevation myocardial infarction (STEMI ) are constantly improving, no-reflow can still lead to poor prognosis .
At present, the exact mechanism of no-reflow remains unclear, but clinical and laboratory findings suggest that it is related to the embolism of the capillary bed, ischemic injury, vascular endothelial dysfunction, production of oxygen free radical , and other factors .
The no-reflow phenomenon is one of complications of poor functional and clinical outcomes for patients with (AMI) .
The no-reflow phenomenon is present in 25% to 30% of patients with (AMI) underwent successful coronary recanalization, as shown by angiography . The myocardial no-reflow phenomenon is associated with a reducution of antegrade myocardial blood flow inspite of an open infarct-related artery in patients with (STEMI ) undergoing (PCI) . Importantly, no-reflow is known to be related to unfavorable clinical outcome and prognosis . The cause of this complex phenomenon is the variable combination of four pathogenetic components: distal atherothrombotic embolization, ischemic injury, reperfusion injury and susceptibility of coronary microcirculation to injury . As a consequence, appropriate strategies are expected to prevent or treat these components are expected to avoid the no-reflow. Coronary reperfusion therapy is widely performed in patients with (AMI) . However, in spite of patency of the infarct-related artery , there is no guarantee of salvage of myocardium at risk of ischemia .The no-reflow phenomenon is found in >30% of patients after thrombolysis or catheter-based (PCI) for (AMI) . It is important, therefore, to be able to predict which lesions are high risk for no reflow before beginning PCI .
Many of the well-accepted risk factors for no-reflow are similar to other well-accepted cardiovascular risk factors, such as hypertension, smoking, dyslipidemia, diabetes, and other inflammatory processes. As such, there are some generally accepted measures associated with a lower incidence of no-reflow following PCI for STEMI. For example, in patients with diabetes, optimal blood sugar control before the procedure can reduce the occurrence of no-reflow .
There are numerous recognized risk factors for the development of coronary artery disease (CAD), one of the best known is the association between blood lipids and CAD . Several prospective studies have established that the risk of cardiac morbidity and mortality is directly related to the concentration of plasma cholesterol. ' The most prevalent view is that the increased risk of myocardial infarction associated with elevated plasma cholesterol levels can be adequately explained on the basis of the increase in number and severity of coronary atherosclerotic vascular lesions . .
Hyperglycemia is associated with The increased mortality in patients with acute myocardial infarction which caused by a larger infarct size, a high incidence of congestive heart failure, and cardiogenic shock, and death after AMI., . However, the underlying mechanisms of these deleterious effects of hyperglycemia are not well understood Uric acid (UA) is a byproduct the terminal steps of purine catabolism, . uric acid synthesis is increased under tissue ischemia. Therefore, elevated uric acid may affect prognosis of (AMI). A few studies have doucomented that UA is associated with therapeutic results in patients with AMI. UA level is appeared to be related to infarct size and hemodynamic derangement. Although prompt restoration of myocardial blood flow is very important for patients with AMI, high levels of UA are doucoumented to be significantly associated with the presence of slow coronary flow
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: alzahraa gamal, master
- Phone Number: 01026181748
- Email: alzahraagamal@gmail.com
Study Contact Backup
- Name: hatem abdel elrahman
- Phone Number: 01005212162
- Email: Hatem19652006@yahoo.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- diabetic patients with ST- elevation myocardial infarction (STEMI ) treated with primary Percutaneous Coronary Intervention ( PCI ) .
Exclusion Criteria:
diabetic patients with ST- elevation myocardial infarction (STEMI ) treated with primary Percutaneous Coronary Intervention ( PCI ) : but have
(1) a history of an unprotected left main artery with severe liver and kidney diseases or coronary artery bypass grafting .
(2) patients who had valvular disease or cardiomyopathy . (3) severe dissection, thromboembolism in other parts, or vasospasm; and known malignancy .
(4) patients with contraindications for anticoagulant therapy, such as active visceral hemorrhage, hemorrhagic stroke, or ischemic stroke within half a year (including transient ischemic attack), or aortic dissection, or patients with hematological diseases complicated with coagulation disorders .
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
detection correlation between DM and no-reflow phenomenon
Time Frame: baseline
|
measurment of random blood sugar in diabetic patients treated with primary Percutaneous Coronary Intervention ( PCI ) .and show its effects on reflow
|
baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
detection correlation between other metabolic factors as serum uric acid and no-reflow phenomenon
Time Frame: baseline
|
Blood samples were obtained before PCI, and the following parameters will be measured :Serum Uric acid : S .UA
|
baseline
|
detection correlation between other metabolic factors as LDL\HDL and no-reflow phenomenon
Time Frame: baseline
|
Blood samples were obtained before PCI, and the following parameters will be measured :(LDL\HDL :(low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotei
|
baseline
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- primary ( PCI )
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myocardial Infarction (AMI)
-
Second Affiliated Hospital, School of Medicine,...RenJi Hospital; Shengjing HospitalCompletedAcute Myocardial Infarction (AMI)China
-
TherOxRecruitingAnterior Acute Myocardial Infarction (AMI)United States
-
NYU Langone HealthCompletedAcute Myocardial Infarction (AMI)United States
-
University of PennsylvaniaCompletedAcute Myocardial Infarction (AMI)United States
-
Kaiser PermanenteAgency for Healthcare Research and Quality (AHRQ)CompletedAcute Myocardial Infarction (AMI)United States
-
Montefiore Medical CenterMedtronicCompletedAcute Myocardial Infarction (AMI)United States
-
Datascope Corp.Duke University; Flinders Medical CentreCompletedAcute Myocardial Infarction (AMI)United States, Germany, Australia, Ireland, India, United Kingdom, Belgium, France, Italy, Netherlands
-
Angel Medical SystemsSymbios ClinicalCompletedAcute Coronary Syndrome | Coronary Occlusion | Acute Myocardial Infarction (AMI)United States
-
Novo Nordisk A/SDuke Clinical Research InstituteNot yet recruitingCardiovascular Risk | Acute Myocardial Infarction (AMI)Canada, China, United States, Germany, Spain, Korea, Republic of, Netherlands, Australia, Italy, Denmark, India, United Kingdom, Argentina, Turkey, Mexico, Malaysia, Czechia, Poland, Brazil, France, Japan, Bulgaria, Greece, Israel
-
Second Affiliated Hospital, School of Medicine,...UnknownMyocardial Infarction (MI) or Acute Myocardial Infarction (AMI)
Clinical Trials on 1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S
-
Assiut UniversityNot yet recruiting